Arrys Therapeutics, Inc. (an affiliate of Kyn Therapeutics) is focused on advancing immuno-metabolism therapy involved with the prostaglandin E2 (PGE2) pathway.
Arrys Therapeutics was launched by OrbiMed and Atlas Venture for the clinical developement of ARY-007. Arrys acquired right for oncology indications and has exclusively subcontracted the development of ARY-007 to Kyn Therapeutics.
In Dec 2017, Arrys Therapeutics acquired worldwide (except for China and Taiwan) development rights of two structurally different Prostaglandin E2 receptor 4 (EP4) antagonists [AAT-007 and AAT-008] from AskAt Inc. Under the terms, AskAt will receive upto $1.2bn in upfront, development, and commercial milestone payments for the molecules.
ARY-007 has demonstrated favorable therapeutic characteristics in human clinical studies for non-oncology indications.
In Dec 2017, Arrys Therapeutics raised $21 Mn in a series A round from Atlas Venture and OrbiMed for the clinical development of ARY-007 (AAT-007, rq-00000007) program.